The Quality of Life of Patients with Newly Diagnosed M1 Prostate Cancer: Experience with EORTC Clinical Trial 30853

European Journal of Cancer

Volumn 32, Issue 1, 1996, Pages 72-77

  Da Silva, Fernando C ^a   Fossa, S D ^b   Aaronson, N K ^c   Serbouti, S ^d   Denis, L ^e   Casselman, J ^f   Whelan, P ^g   Hetherington, J ^h   Fava, C ⁱ   Richards, B ^j   Robinson, M R G ^k  

^a Hospital do Desterro   (Portugal)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d EORTC DATA CENTER   (Belgium)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f Algemeen Ziekenhuis Damiaan Oostende   (Belgium)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h PRINCESS ROYAL HOSPITAL   (United Kingdom)

ⁱ OSPEDALE DI CIRCOLO   (Italy)

^j YORK HOSPITAL   (United Kingdom)

^k Pontefract General Infirmary   (United Kingdom)

more..

Author keywords

Hormonal treatment; M1 prostate cancer; Quality of life

Indexed keywords

ANTIANDROGEN; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUTAMIDE; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; MALE; MEDICAL STAFF, HOSPITAL; MIDDLE AGED; ORCHIECTOMY; PATIENT COMPLIANCE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 0029928271     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00402-5     Document Type: Article

References (20)

1. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients. J Chron Dis 1981, 34, 585-597.
2. Aaronson NK, Meyerowitz BE, Bard M, et al. Quality of life research in oncology. Past achievements and future priorities. Cancer 1991, 67, 839-843.
3. Olschewski M, Schulgen G, Schumacher M, et al. Quality of life assessment in clinical cancer research. Br J Cancer 1994, 70, 1-5.
4. Sprangers MAG, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol 1992, 45, 743-760.
5. Slevin ML, Plant H, Lynch D, et al. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988, 57, 287-295.
6. Ackermann R, Frohmüller HGW. Complications and morbidity following radical prostatectomy. World J Urol 1983, 1, 62-67.
7. Herr HW, Kornblith AB, Ofman U. A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 1993, 71, 1143-1150.
8. Kornblith AB, Herr HW, Ofman US, et al. Quality of patients with prostate cancer and their spouses. Cancer 1994, 73, 2791-2802.
9. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Quality of life and psychosocial status in stage D prostate cancer. Quality Life Res 1992, 1, 323-330.
10. Parmar H, Phillips Rh, Lightman SL, et al. How would you like to have an orchiectomy for advanced prostatic cancer? AmJ Clin Oncol 1988, 11, 160-168.
11. Presant CA, Soloway M, Klioze SS, et al. Buserelin treatment of advanced prostatic carcinoma. Long-term follow-up of antitumor responses and improved quality of life. Cancer 1987, 59, 1713-1716.
12. Tannock I, Gospidarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose Prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989, 7, 590-597.
13. Fosså SD, Aaronson NK, Newling D, et al. Subjective response to treatment of hormone-resistant metastatic prostatic cancer. Eur J Cancer Clin Oncol 1990, 26, 1133-1136.
14. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostatic cancer. Int J Radiat Oncol Biol Phys 1993, 25, 805-813.
15. Moore MJ, Osoba D, Murphy K, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994, 12, 689-694.
16. Fossa SD. Quality of life after palliative radiotherapy in patients with hormone-resistant prostate cancer: single institution experience. Br J Urol 1994, 74, 345-351.
17. Denis LJ, Whelan P, Carneiro de Moura JL, et al. Goserelin acetate and Flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 1993, 42, 119-130.
18. Nunnally JC. Psychometric Theory. New York, McGraw-Hill, 1978.
19. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85, 365-376.
20. Sprangers MAG, Cull A, Bjordal K, Groenvold M, Aaronson NK. The European Organization for Research and Treatment of Cancer approach to quality of life assessment: guidelines for developing questionnaire modules. Quality Life Res 1993, 2, 287-295.